We pioneer transformative treatments through viral vector technology and comprehensive services. Discover our dedication to empowering breakthroughs driven by our mission, vision, and expert leadership team.
To revolutionize lentiviral vector production by providing cost-effective, rapid, and globally accessible solutions that empower our partners to bring transformative therapies to patients in need.
Values
Boldness - innovating fearlessly to accelerate life-changing therapies. Integrity - upholding ethics and transparency for trust. Ownership - embracing responsibility for quality results.
Vision
Revolutionize cell and gene therapies by seamlessly integrating our viral vector expertise with end-to-end services, fostering innovation, accessibility, and personalized care worldwide.
Partners
Bridgewest Ventures
BioViros is proudly supported by Bridgewest Ventures NZ LP. Bridgewest Ventures is part of the Bridgewest Group and has a long track record of successfully incubating and launching major global innovation-led companies. Bridgewest’s deep technology experience is wide-ranging and includes drug discovery and deep research into health technology, with expertise in novel CAR T-cell platforms. Bridgewest Ventures leverage their extensive connections, international reach, and commercialization experience to transform innovative opportunities into world-class companies.
Callaghan Innovation is New Zealand’s innovation agency. It activates innovation and helps businesses grow faster for a better New Zealand. The government agency delivers a range of innovation and R&D services to suit each stage of business growth. Callaghan Innovation staff, including more than 200 of New Zealand’s leading scientists and engineers, empower innovators by connecting people, opportunities, and networks and providing tailored technical solutions, skills and capability development programmes, and grants co-funding.
